This Article Abstract Full Text Full Text (PDF) View Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (42) Citing Articles via Google Scholar Google Scholar Articles by Kandzari, D. E. Search for Related Content PubMed Articles by Kandzari, D. E.

Comparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease

A Randomized Controlled Trial

David E. Kandzari, MD, FACC^_*,_*, Martin B. Leon, MD, FACC, Jeffrey J. Popma, MD, FACC, Peter J. Fitzgerald, MD, FACC^||, Charles O’Shaughnessy, MD, FACC^#, Michael W. Ball, MD, FACC^_**, Mark Turco, MD, FACC, Robert J. Applegate, MD, FACC, Paul A. Gurbel, MD, FACC, Mark G. Midei, MD, FACC, Sejal S. Badre, MS, Laura Mauri, MD, MSc, FACC, Kweli P. Thompson, MD^¶, LeRoy A. LeNarz, MD^¶, Richard E. Kuntz, MD, FACC^¶ for the ENDEAVOR III Investigators

^_* Duke Clinical Research Institute, Durham, North Carolina
Baptist Medical Center and Wake Forest University, Winston-Salem, North Carolina
Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
Harvard Clinical Research Institute and Brigham and Women’s Hospital, Boston, Massachusetts
^|| Stanford University Medical Center, Palo Alto, California
^¶ Medtronic, Inc., Santa Rosa, California
^# North Ohio Heart Center, Elyria, Ohio
^_** St. Vincent’s Hospital, Indianapolis, Indiana
Washington Adventist Hospital, Takoma Park, Maryland
Sinai Center for Thrombosis Research, Baltimore, Maryland
St. Joseph’s Medical Center, Towson, Maryland.

View larger version (25K): [in this window] [in a new window] [Download PPT slide]   Figure 1 Kaplan-Meier event-free survival to 9 months for patients treated with zotarolimus- (ZES) and sirolimus-eluting (SES) stents. MACE = major adverse cardiac events; TLR = target lesion revascularization; TVF = target vessel failure.

View larger version (27K): [in this window] [in a new window] [Download PPT slide]   Figure 2 Logistic regression relationship between late lumen loss and target lesion revascularization (TLR) for patients treated with zotarolimus-eluting stents.